[go: up one dir, main page]

ATE538386T1 - Nachweis von krebs anhand von erhöhten bcl-2- konzentrationen - Google Patents

Nachweis von krebs anhand von erhöhten bcl-2- konzentrationen

Info

Publication number
ATE538386T1
ATE538386T1 AT07763533T AT07763533T ATE538386T1 AT E538386 T1 ATE538386 T1 AT E538386T1 AT 07763533 T AT07763533 T AT 07763533T AT 07763533 T AT07763533 T AT 07763533T AT E538386 T1 ATE538386 T1 AT E538386T1
Authority
AT
Austria
Prior art keywords
bcl
cancer
concentrations
detection
binds
Prior art date
Application number
AT07763533T
Other languages
English (en)
Inventor
Patricia Kruk
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Application granted granted Critical
Publication of ATE538386T1 publication Critical patent/ATE538386T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT07763533T 2006-02-09 2007-02-09 Nachweis von krebs anhand von erhöhten bcl-2- konzentrationen ATE538386T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77167706P 2006-02-09 2006-02-09
PCT/US2007/003608 WO2007092627A2 (en) 2006-02-09 2007-02-09 Detection of cancer by elevated levels of bcl-2

Publications (1)

Publication Number Publication Date
ATE538386T1 true ATE538386T1 (de) 2012-01-15

Family

ID=38345845

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07763533T ATE538386T1 (de) 2006-02-09 2007-02-09 Nachweis von krebs anhand von erhöhten bcl-2- konzentrationen

Country Status (16)

Country Link
US (4) US8034549B2 (de)
EP (1) EP1996940B1 (de)
JP (1) JP4896994B2 (de)
KR (1) KR20080114689A (de)
CN (1) CN101384903A (de)
AT (1) ATE538386T1 (de)
AU (1) AU2007212278A1 (de)
BR (1) BRPI0707645B8 (de)
CA (1) CA2642051C (de)
IL (1) IL192866A (de)
NO (1) NO20083820L (de)
NZ (1) NZ570008A (de)
RU (1) RU2436098C2 (de)
SG (1) SG169395A1 (de)
WO (1) WO2007092627A2 (de)
ZA (1) ZA200805787B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307428D0 (en) * 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) * 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) * 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US20050221339A1 (en) * 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) * 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US20100137163A1 (en) 2006-01-11 2010-06-03 Link Darren R Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors
AU2007212278A1 (en) 2006-02-09 2007-08-16 University Of South Florida Detection of cancer by elevated levels of Bcl-2
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2021113A2 (de) 2006-05-11 2009-02-11 Raindance Technologies, Inc. Mikrofluidische vorrichtungen
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2007137187A2 (en) * 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
US8772046B2 (en) * 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) * 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2009055813A1 (en) * 2007-10-25 2009-04-30 The Research Foundation Of State University Of New York Apparatus and method of detection and localized treatment of abnormal conditions
EP4047367A1 (de) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Verfahren zum nachweis von zielanalyten unter verwendung von tropfenbibliotheken
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
US20110218155A1 (en) * 2008-10-10 2011-09-08 Dana-Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
EP2411148B1 (de) 2009-03-23 2018-02-21 Raindance Technologies, Inc. Manipulation von mikrofluidiktröpfchen
US8328795B2 (en) * 2009-04-03 2012-12-11 Candela Corporation Skin resurfacing at 1930 nm
PT2456889E (pt) * 2009-07-24 2014-11-21 Geadic Biotec Aie Marcadores para o cancro do endométrio
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
AU2010315400B2 (en) * 2009-10-27 2016-07-21 Caris Mpi, Inc. Molecular profiling for personalized medicine
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
JP5934657B2 (ja) 2010-02-12 2016-06-15 レインダンス テクノロジーズ， インコーポレイテッド デジタル検体分析
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
SG189957A1 (en) * 2010-11-05 2013-06-28 Morphotek Inc Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
WO2012109600A2 (en) 2011-02-11 2012-08-16 Raindance Technologies, Inc. Methods for forming mixed droplets
EP3736281A1 (de) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
JP2014512803A (ja) * 2011-02-23 2014-05-29 ムドスーレ エルティディ 個人的腫瘍プロファイリング治療のための組成物及び方法
US9556470B2 (en) 2011-06-02 2017-01-31 Raindance Technologies, Inc. Enzyme quantification
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP2729486B1 (de) * 2011-07-09 2017-12-13 The Regents of The University of California Auf leukämiestammzellen zielende liganden und verfahren zu ihrer verwendung
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013035095A1 (en) * 2011-09-08 2013-03-14 Ben-Gurion University Of The Negev Research And Development Authority Methods for diagnosing cancer
US20130078319A1 (en) * 2011-09-22 2013-03-28 Memorial Sloan-Kettering Cancer Center Detection of ovarian cancer
AU2012325697B2 (en) * 2011-10-21 2015-11-26 Decimadx, Llc Point-of care immunoassay for quantitative small analyte detection
EP3495817B1 (de) 2012-02-10 2024-10-16 Bio-Rad Laboratories, Inc. Molekulardiagnostischer screeningtest
EP2844768B1 (de) 2012-04-30 2019-03-13 Raindance Technologies, Inc. Digitale analyse von analyten
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
SG11201601060RA (en) * 2013-08-19 2016-03-30 Biontech Diagnostics Gmbh Methods and kits for the molecular subtyping of tumors
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
EP3825411A1 (de) 2014-06-18 2021-05-26 Clear Gene, Inc. Verfahren, zusammensetzungen und vorrichtungen zur schnellanalyse von biologischen markern
HK1243454A1 (zh) 2014-09-17 2018-07-13 Hologic, Inc. 部分裂解和测定的方法
GB201417281D0 (en) * 2014-09-30 2014-11-12 Ge Healthcare Uk Ltd Methods and devices relating to the detection of oral cancer biomarkers
JP5995117B2 (ja) * 2015-01-26 2016-09-21 国立大学法人 筑波大学 可溶型ｃｄ１５５タンパク質を用いた癌の検出方法
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
AU2016369603A1 (en) 2015-12-18 2018-07-05 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
US12275994B2 (en) 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
EP3817756A4 (de) * 2018-07-05 2022-03-30 Ovation Diagnostics LLC Bcl-2-antikörper und immunoassay zur krebsdiagnose
CN109374897B (zh) * 2018-11-22 2021-11-02 大连大学 一种用于肝癌检测的试剂盒
AU2020398476A1 (en) * 2019-12-06 2022-07-14 Proteina, Co., Ltd. Method for predicting reactivity to drug targeting BCL2 family protein
EP4138845A4 (de) * 2020-04-21 2024-10-09 Carlo M. Croce Verfahren zum nachweis und zur behandlung von krebs mit dem verlust von mir15- und mir16-expression
CN115335704A (zh) * 2020-05-12 2022-11-11 隆萨休斯敦股份有限公司 用于检测腺相关病毒的方法和试剂盒
CN111679076A (zh) * 2020-06-15 2020-09-18 吉林医药学院 一种用于检测cyclinD1和BCL-2抗体的检测试剂盒
EP4511513A1 (de) * 2022-06-01 2025-02-26 Northeastern University Massenetikett-dna-adduktomik mit verbesserter spezifität
WO2025075824A1 (en) * 2023-10-02 2025-04-10 Siemens Healthcare Diagnostics Inc. Urine sediment interface with probabilistic classification binning and methods of producing and using same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4260678A (en) 1979-02-23 1981-04-07 Corning Glass Works Determining creatine kinase isoenzmes via immobilized antibody-isoenzyme complexes
US4381291A (en) 1979-02-23 1983-04-26 Ab Fortia Measurement of free ligands
US4343312A (en) 1979-04-16 1982-08-10 Vitafin N.V. Pacemaker output circuit
FR2455743A1 (fr) 1979-05-02 1980-11-28 Goella Laboratoires Procede et dispositif pour le dosage des lipoproteines seriques
US4357311A (en) 1980-10-03 1982-11-02 Warner-Lambert Company Substrate for immunoassay and means of preparing same
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
JPS59500735A (ja) 1983-04-18 1984-04-26 エス・ア−ル・アイ・インタ−ナシヨナル 人間の癌診断のための方法および試験キツト
US4582789A (en) 1984-03-21 1986-04-15 Cetus Corporation Process for labeling nucleic acids using psoralen derivatives
US4617261A (en) 1984-03-21 1986-10-14 Cetus Corporation Process for labeling nucleic acids and hybridization probes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5356817A (en) 1988-06-09 1994-10-18 Yale University Methods for detecting the onset, progression and regression of gynecologic cancers
US5312922A (en) 1992-04-06 1994-05-17 Nordion International Inc. Europium and terbium chelators for time-resolved fluorometric assays
EP0689673B1 (de) * 1993-03-17 1997-07-02 Akzo Nobel N.V. Vorrichtung zur Bestimmung einer spezifisch reagierenden Substanz
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
US5695944A (en) 1995-05-05 1997-12-09 Thomas Jefferson University Modulation of bcl-2 phosphorylation
US6811995B1 (en) 1996-04-26 2004-11-02 Children's Medical Center Corporation Non-invasive enzyme screen for cancer
US5821082A (en) 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
DE19936618A1 (de) * 1999-08-04 2001-03-15 Monotec Gmbh Diagnostisches Kit und dessen Verwendung
AU2001233156A1 (en) 2000-02-01 2001-08-14 Human Genome Sciences, Inc. Bcl-2-like polynucleotides, polypeptides, and antibodies
KR100414637B1 (ko) * 2000-02-08 2004-01-13 (주)에스제이바이오메드 사람 미토콘드리아 아데닐레이트 키나제 이소자임들에대한 항체와 면역학적 제제 및 심장질환 진단키트
WO2001075177A2 (en) 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tumor markers in ovarian cancer
US6492127B2 (en) * 2001-01-23 2002-12-10 Varian, Inc. Lateral flow testing device with on-board chemical reactant
DE60221151T2 (de) * 2001-05-07 2008-03-20 The Burnham Institute, La Jolla Verfahren zur bestimmung der prognose von krebspatienten mittels tucan
AU2002309668A1 (en) 2001-05-07 2002-11-18 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
AU2003253986A1 (en) 2002-03-13 2003-09-29 Genomic Health Gene expression profiling in biopsied tumor tissues
KR20030092378A (ko) * 2002-05-29 2003-12-06 박영미 고형암의 진행 정도를 진단하는 방법 및 키트
US20040002168A1 (en) * 2002-06-13 2004-01-01 Neuropro Technologies, Inc. Apparatus and methods for detecting cerebrospinal fluid
CN1402004A (zh) * 2002-09-27 2003-03-12 江西中德生物工程有限公司 一种免疫层析一步法检测β－肾上腺素激动剂类药物的方法及试纸的制备
US20040137538A1 (en) * 2003-01-10 2004-07-15 Bradford Sherry A. Cancer comprehensive assay kit for identifying cancer protein patterns
US7288383B2 (en) 2003-01-15 2007-10-30 The Brigham And Women's Hospital, Inc. Eosinophil-derived neurotoxin as a marker for ovarian cancer
WO2006039542A1 (en) * 2004-09-30 2006-04-13 Quidel Corporation Analytical devices with primary and secondary flow paths
AU2007212278A1 (en) 2006-02-09 2007-08-16 University Of South Florida Detection of cancer by elevated levels of Bcl-2

Also Published As

Publication number Publication date
US8034549B2 (en) 2011-10-11
WO2007092627A9 (en) 2007-10-18
BRPI0707645A2 (pt) 2011-05-10
ZA200805787B (en) 2009-05-27
NZ570008A (en) 2011-10-28
US20110318763A1 (en) 2011-12-29
JP2009526234A (ja) 2009-07-16
AU2007212278A1 (en) 2007-08-16
RU2436098C2 (ru) 2011-12-10
US20160258960A1 (en) 2016-09-08
RU2008136193A (ru) 2010-03-20
WO2007092627A2 (en) 2007-08-16
IL192866A (en) 2013-04-30
CA2642051C (en) 2017-01-24
CN101384903A (zh) 2009-03-11
BRPI0707645B1 (pt) 2019-04-09
US20190072556A1 (en) 2019-03-07
SG169395A1 (en) 2011-03-30
KR20080114689A (ko) 2008-12-31
EP1996940B1 (de) 2011-12-21
NO20083820L (no) 2008-11-07
US11156613B2 (en) 2021-10-26
JP4896994B2 (ja) 2012-03-14
WO2007092627A3 (en) 2008-11-13
EP1996940A2 (de) 2008-12-03
BRPI0707645B8 (pt) 2021-07-27
CA2642051A1 (en) 2007-08-16
EP1996940A4 (de) 2009-10-21
US20080009005A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
ATE538386T1 (de) Nachweis von krebs anhand von erhöhten bcl-2- konzentrationen
WO2008134526A3 (en) Glycoprotein profiling of bladder cancer
NO20076656L (no) Forbedrede immunoassay metoder
ATE556030T1 (de) Ultrasensitiver nachweis von analyten
WO2008066607A3 (en) Device for detection of molecules in biological fluids
CY1113686T1 (el) Συσκευη bio-αισθητηρα και οι μεθοδοι χρησης της
DE602005013225D1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
ATE438853T1 (de) Diagnostische testvorrichtung
TW200720441A (en) New labelling strategies for the sensitive detection of analytes
EP2340300A4 (de) Verfahren zur erkennung von analyten
WO2008021290A9 (en) Organ-specific proteins and methods of their use
AU2004256206A1 (en) Device and method for simultaneous carrying out of blood group determination, serum cross-check and antibody detection test
WO2010065781A3 (en) Lateral flow strip assay with immobilized conjugate
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
ATE541054T1 (de) Bio-barcode erkennung für zielmoleküle
WO2005086647A3 (en) Immuno-pcr method for the detection of a biomolecule in a test sample
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
WO2009020782A3 (en) Oral fluid assays for the detection of heavy metal exposure
PL1977244T3 (pl) Rozróżnianie bakteryjnego i wirusowego zapalenia opon mózgowych
WO2020264444A3 (en) Assay method for point of care quantification of an immunophilin-binding immunosuppressant drug
WO2008072192A3 (en) Biological assay substrate and method and device for producing such substrate
ATE495267T1 (de) Diagnostisches verfahren zum nachweis von helicobacter pylori
CY1109461T1 (el) Βελτιωμενες μεθοδοι ανοσολογικου προσδιορισμου
EP2444812A3 (de) Verbesserte Immunoassayverfahren
DE50203136D1 (de) Verfahren zum Nachweis von Analyten in Proben mittels Analysenelementen